Diabetic macular edema pipeline review, h1 2013 - Reports Corner

1,058 views

Published on

Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects.

https://www.reportscorner.com/reports/15422/Diabetic-Macular-Edema---Pipeline-Review,-H1-2013/

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

Diabetic macular edema pipeline review, h1 2013 - Reports Corner

  1. 1. RCReports CornerDiabetic Macular Edema - Pipeline Review, H12013
  2. 2. DescriptionDescriptionReports Cornerwww.reportscorner.comGlobal Markets Directs, Diabetic Macular Edema - PipelineReview, H1 2013, provides an overview of the indicationstherapeutic pipeline. This report provides information on thetherapeutic development for Diabetic Macular Edema, completewith latest updates, and special features on late-stage anddiscontinued projects.
  3. 3. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com"Global Markets Directs, Diabetic Macular Edema - PipelineReview, H1 2013, provides an overview of the indicationstherapeutic pipeline. This report provides information on thetherapeutic development for Diabetic Macular Edema, completewith latest updates, and special features on late-stage anddiscontinued projects. It also reviews key players involved in thetherapeutic development for Diabetic Macular Edema. DiabeticMacular Edema - Pipeline Review, Half Year is built using data andinformation sourced from Global Markets Directs proprietarydatabases, Company/University websites, SEC filings, investorpresentations and featured press releases fromcompany/university sites and industry-specific third partysources, put together by Global Markets Directs team.Note*:Certain sections in the report may be removed or altered based onthe availability and relevance of data for the indicated disease.
  4. 4. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comScope- A snapshot of the global therapeutic scenario for DiabeticMacular Edema.- A review of the Diabetic Macular Edemaproducts under development by companies anduniversities/research institutes based on information derived fromcompany and industry-specific sources.- Coverage of productsbased on various stages of development ranging from discoverytill registration stages.- A feature on pipeline projects on the basisof monotherapy and combined therapeutics.- Coverage of theDiabetic Macular Edema pipeline on the basis of route ofadministration and molecule type.- Key discontinued pipelineprojects.- Latest news and deals relating to the products.Reasonsto buy- Identify and understand important and diverse types oftherapeutics under development for Diabetic Macular Edema.-Identify emerging players with potentially strong product portfolioand design effective counter-strategies to gain competitiveadvantage.-
  5. 5. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comPlan mergers and acquisitions effectively by identifying players ofthe most promising pipeline.- Devise corrective measures forpipeline projects by understanding Diabetic Macular Edemapipeline depth and focus of Indication therapeutics.- Develop anddesign in-licensing and out-licensing strategies by identifyingprospective partners with the most attractive projects to enhanceand expand business potential and scope.- Modify the therapeuticportfolio by identifying discontinued projects and understandingthe factors that drove them from pipeline."
  6. 6. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comTable of ContentsTable of Contents 2List of Tables 6List of Figures 7Introduction 8Global Markets Direct Report Coverage 8Diabetic Macular Edema Overview 9Therapeutics Development 10An Overview of Pipeline Products for Diabetic Macular Edema 10Diabetic Macular Edema Therapeutics under Development by Companies 12Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes 15Late Stage Products 16Comparative Analysis 16Mid Clinical Stage Products 17
  7. 7. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comComparative Analysis 17Early Clinical Stage Products 18Comparative Analysis 18Discovery and Pre-Clinical Stage Products 19Comparative Analysis 19Diabetic Macular Edema Therapeutics - Products under Development by Companies 20Diabetic Macular Edema Therapeutics - Products under Investigation by Universities/Institutes 22Companies Involved in Diabetic Macular Edema Therapeutics Development 23F. Hoffmann-La Roche Ltd. 23Allergan, Inc. 24pSivida Corp. 25Eli Lilly and Company 26GlaxoSmithKline plc 27Quark Pharmaceuticals, Inc. 28Santen Pharmaceutical Co., Ltd. 29
  8. 8. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comLux Biosciences, Inc. 30Novagali Pharma SA 31Astellas Pharma Inc. 32iCo Therapeutics Inc. 33Mesoblast Ltd 34NicOx SA 35SANWA KAGAKU KENKYUSHO CO.,LTD. 36Regeneron Pharmaceuticals, Inc. 37ThromboGenics NV 38Foamix Ltd. 39Molecular Partners AG 40Aciont Inc. 41Charlesson LLC. 42Icon Bioscience, Inc. 43Eleven Biotherapeutics 44
  9. 9. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comAmpio Pharmaceuticals, Inc. 45Diabetic Macular Edema - Therapeutics Assessment 46Assessment by Monotherapy Products 46Assessment by Route of Administration 47Assessment by Molecule Type 49Drug Profiles 52ranibizumab - Drug Profile 52Product Description 52Mechanism of Action 52R&D Progress 52darapladib - Drug Profile 55Product Description 55Mechanism of Action 55R&D Progress 55iCo-007 - Drug Profile 57
  10. 10. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comProduct Description 57Mechanism of Action 57R&D Progress 57dexamethasone acetate - Drug Profile 59Product Description 59Mechanism of Action 59R&D Progress 59ocriplasmin - Drug Profile 61Product Description 61Mechanism of Action 61R&D Progress 61Eylea - Drug Profile 64Product Description 64Mechanism of Action 64R&D Progress 64
  11. 11. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comdexamethasone dipropionate - Drug Profile 67Product Description 67Mechanism of Action 67R&D Progress 67Drug For Diabetic Macular Edema - Drug Profile 68Product Description 68Mechanism of Action 68R&D Progress 68dexamethasone acetate - Drug Profile 69Product Description 69Mechanism of Action 69R&D Progress 69PF-655 - Drug Profile 70Product Description 70Mechanism of Action 70R&D Progress 70
  12. 12. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comfluocinolone acetonide - Drug Profile 72Product Description 72Mechanism of Action 72R&D Progress 72CLT-003 - Drug Profile 74Product Description 74Mechanism of Action 74R&D Progress 74betamethasone - Drug Profile 75Product Description 75Mechanism of Action 75R&D Progress 75danazol - Drug Profile 76Product Description 76Mechanism of Action 76
  13. 13. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comR&D Progress 76MP-0112 - Drug Profile 77Product Description 77Mechanism of Action 77R&D Progress 77ruboxistaurin - Drug Profile 79Product Description 79Mechanism of Action 79R&D Progress 79sirolimus - Drug Profile 81Product Description 81Mechanism of Action 81R&D Progress 81minocycline - Drug Profile 83Product Description 83
  14. 14. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comMechanism of Action 83R&D Progress 83AKB-9778 - Drug Profile 85Product Description 85Mechanism of Action 85R&D Progress 85KH-902 - Drug Profile 87Product Description 87Mechanism of Action 87R&D Progress 87LX-213 - Drug Profile 89Product Description 89Mechanism of Action 89R&D Progress 89Mesenchymal Precursor Cells For Diabetic Macular Edema - Drug Profile 90
  15. 15. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comProduct Description 90Mechanism of Action 90R&D Progress 90NCX-422 - Drug Profile 91Product Description 91Mechanism of Action 91R&D Progress 91ALG-1001 - Drug Profile 92Product Description 92Mechanism of Action 92R&D Progress 92Steroid For Diabetic Macular Edema - Drug Profile 94Product Description 94Mechanism of Action 94R&D Progress 94
  16. 16. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comPlasma Kallikrein Inhibitors Programme - Drug Profile 95Product Description 95Mechanism of Action 95R&D Progress 95Plasma Kallikrein Inhibitors Programme - Drug Profile 97Product Description 97Mechanism of Action 97R&D Progress 97Plasma Kallikrein Inhibitors Oral Programme - Drug Profile 98Product Description 98Mechanism of Action 98R&D Progress 98EBI-018 - Drug Profile 99Product Description 99Mechanism of Action 99
  17. 17. Table of ContentsTable of Contentswww.reportscorner.comR&D Progress 99Vascular Adhesion Protein-1 Inhibitor - Drug Profile 100Product Description 100Mechanism of Action 100R&D Progress 100Diabetic Macular Edema Therapeutics - Drug Profile Updates 101Diabetic Macular Edema Therapeutics - Discontinued Products 123Diabetic Macular Edema Therapeutics - Dormant Products 124Diabetic Macular Edema - Product Development Milestones 126Featured News & Press Releases 126Oct 05, 2012: NICE Publishes Draft Guidance On Novartiss Ranibizumab For Diabetic Macular EdemaAfter Rapid Review 126Sep 19, 2012: Aerpio Therapeutics Initiates Phase Ib/IIa Trial Of AKB-9778 In Diabetic Macular Edema 127Sep 05, 2012: NICE Accepts Alimera Sciencess Iluvien Subgroup Data For Review 127Aug 10, 2012: FDA Approves Lucentis For Treatment Of Diabetic Macular Edema 128Aug 08, 2012: NICE Turns Down Alimeras Iluvien For Treatment Of Diabetic Macular Edema 130
  18. 18. Table of ContentsTable of Contentswww.reportscorner.comAug 01, 2012: Ampio Announces Successful Pre-IND Meeting With Ophthalmology Division Of FDA OnOptina For Treatment Of Diabetic Macular Edema 131Aug 01, 2012: pSivida Reports Alimeras Intention To Resubmit Application To FDA For ILUVIEN In DMEUsing Data From Completed Trials 132Jul 26, 2012: Alimera Sciencess ILUVIEN Receives Marketing Authorization In Germany For Treatment OfChronic Diabetic Macular Edema 132Jul 26, 2012: FDA Advisory Committee Recommends Approval Of Roches Lucentis For Treatment OfDiabetic Macular Edema 133Jul 24, 2012: FDA Reviews Lucentis Ahead Of Panel Vote 134Appendix 135Methodology 135Coverage 135Secondary Research 135Primary Research 135Expert Panel Validation 135Contact Us 136Disclaimer 13R&D Progress 70
  19. 19. For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/15422/Diabetic-Macular-Edema---Pipeline-Review,-H1-2013/
  20. 20. Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com

×